



Starting your patients on treatment


A digital educational tool to help you have more productive conversations with your patients.

Please see Important Safety Information throughout this presentation and [full Prescribing Information](#).

RYTARY[®]
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

HOW DOES RYTARY WORK?

Every RYTARY capsule contains a unique combination of time-released CD/LD beads



CD/LD, carbidopa/levodopa; IR, immediate release.

INDICATION

RYTARY (carbidopa and levodopa) extended-release capsules is a prescription medication that contains a combination of carbidopa and levodopa for the treatment of Parkinson's disease, Parkinson's disease caused by infection or inflammation of the brain, or Parkinson's disease like symptoms that may result from carbon monoxide or manganese poisoning.

IMPORTANT SAFETY INFORMATION


Do not take RYTARY with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors because taking these two drugs within two weeks of each other can result in high blood pressure.

Please see additional Important Safety Information throughout this presentation and full Prescribing Information.

RYTARY
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

WHAT MAKES RYTARY DIFFERENT?

RYTARY can fill in the troughs and smooth out the peaks created by IR CD/LD



RYTARY was given every 6 hours while IR CD/LD was given every 3 hours.

*Percentage deviation from LD average concentration at steady state.

IMPORTANT SAFETY INFORMATION (continued)

Taking RYTARY may result in falling asleep while engaged in normal activities, even without warning and as late as one year after starting RYTARY. This may affect your ability to drive or operate machinery. Do not do anything that requires alertness until you know how RYTARY affects you.

Please see additional Important Safety Information throughout this presentation and full Prescribing Information.

RYTARY
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

HOW CAN RYTARY HELP?

Taking RYTARY may result in:

2X reduction
in “off” time

compared with immediate-release carbidopa/
levodopa (IR CD/LD)

In a clinical study, people with advanced Parkinson’s disease taking RYTARY experienced a 13.1% reduction in “off” time during waking hours (compared with only 6.2% for people taking IR CD/LD)*; $P < 0.0001$ vs IR CD/LD.

- RYTARY at study start and study end†: 36.9% to 23.8%
- IR CD/LD at study start and study end†: 36.0% to 29.8%

*“Waking hours” is a term used to describe the hours during a day in which you are awake. The primary measurement in this study was the percentage of “off” time during waking hours.

†Study end = Week 22 or early termination.

IMPORTANT SAFETY INFORMATION (continued)

Tell your healthcare provider if you have any heart conditions, especially if you have had a heart attack or irregular heartbeats; if you experience hallucinations or abnormal thoughts and behaviors (such as excessive suspicion, believing things that are not real, confusion, agitation, aggressive behavior, and disorganized thinking), if you have intense urges to gamble, increased sexual urges, other intense urges, and the inability to control those urges; if abnormal involuntary movements appear or get worse during treatment with RYTARY; or if you have ever had a peptic ulcer or glaucoma.

Please see additional Important Safety Information throughout this presentation and full Prescribing Information.

RYTARY
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

HOW IS RYTARY TAKEN?

RYTARY is not a one-dose-fits-all type of medication

As you begin your RYTARY treatment plan, here are some key points to keep in mind:



Your dose of RYTARY will not be the same as your dose of IR CD/LD



Your dose may need to be adjusted



Finding the right dose may take time

This is why it's important to be open and honest about your progress, especially if you're experiencing:

Too much “off” time

A delay in “on” time

Too much dyskinesia

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects that may occur with RYTARY include nausea, dizziness, headache, sleeplessness, abnormal dreams, dry mouth, abnormal involuntary movements, anxiety, constipation, vomiting, and low blood pressure upon rising.

Some patients taking RYTARY have experienced suicidal thoughts or have attempted suicide. Tell your healthcare provider if you have thoughts of suicide or have attempted suicide.

Please see additional Important Safety Information throughout this presentation and full Prescribing Information.

RYTARY
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

HOW IS RYTARY TAKEN?

Additional tips for taking RYTARY

Like with any medication, it's important that you understand how to take it. For example:



DO

Take your doses of RYTARY with or without food, and you may want to consider taking your first dose of the day 1 to 2 hours before eating.



DO

Swallow RYTARY capsules whole. Or, you may sprinkle the entire contents of both halves of the capsule on a small amount of applesauce (1 to 2 tablespoons) and consume the mixture immediately.



DON'T

Chew, cut, or crush RYTARY capsules.

You may also want to avoid eating foods that are high in fat, calories, and/or protein, because these types of foods may affect how your body absorbs RYTARY.

NOTE: If you've been given a digital RYTARY Welcome Kit, use the Treatment Journal to help keep up with your RYTARY treatment plan. Your healthcare provider may also give you a Treatment Tracker, which you can fill in with your specific dosing information.

IMPORTANT SAFETY INFORMATION (continued)

Notify your healthcare provider if you become pregnant or intend to become pregnant during therapy or if you intend to breast-feed or are breast-feeding an infant.

Please see additional Important Safety Information throughout this presentation and [full Prescribing Information](#).

RYTARY
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

WHAT SUPPORT IS AVAILABLE?

PHIL PhilRx makes it as easy as 1-2-3!

PhilRx works with your insurance

All eligible savings will be applied to your co-pay

PhilRx will contact you through a text message and phone call to enroll

RYTARY is also available at your local pharmacy.

IMPORTANT SAFETY INFORMATION (continued)

Talk to your healthcare provider before you lower the dose or stop taking RYTARY, as this may result in serious side effects. Call your healthcare provider immediately if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness.

Please see additional Important Safety Information throughout this presentation and full Prescribing Information.

RYTARY
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

WHAT SUPPORT IS AVAILABLE?

The RYTARY Welcome Kit

A collection of resources designed to support you in your journey

The Welcome Kit contains the following materials:



Welcome
Card



RYTARY
Quick-start
Guide



RYTARY
Brochure



RYTARY
Treatment
Journal

IMPORTANT SAFETY INFORMATION (continued)

Take RYTARY as instructed. You may take RYTARY with or without food; however, taking RYTARY with food may decrease or delay its effect. For this reason, consider taking the first dose of the day about 1 to 2 hours before eating. Swallow RYTARY whole; do not chew, divide, or crush. If you have difficulty swallowing the capsule, twist apart both halves and sprinkle the entire contents of both halves of the capsule on a small amount of applesauce (1 to 2 tablespoons). Consume the mixture immediately. Do not store the drug/food mixture for future use.

Please see additional Important Safety Information throughout this presentation and [full Prescribing Information](#).

RYTARY
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg

IMPORTANT SAFETY INFORMATION (continued)

Note: This information is intended to aid in the safe and effective use of RYTARY. It is not a disclosure of all possible adverse or intended effects. Tell your healthcare provider if you have any side effects while taking RYTARY. He or she can make adjustments that may reduce these effects.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information. For more information go to RYTARY.com and/or talk to your healthcare provider.

Please see additional Important Safety Information throughout this presentation and [full Prescribing Information](#).



RYTARY is a registered trademark of Amneal Pharmaceuticals LLC.
© 2024 Amneal Pharmaceuticals LLC.
Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.
All rights reserved. PP-ADW-RYT-US-0052 10/2024

RYTARY[®]
(carbidopa and levodopa)
EXTENDED-RELEASE CAPSULES
23.75 mg/95 mg • 36.25 mg/145 mg
48.75 mg/195 mg • 61.25 mg/245 mg